Tresorit Secures $11.5M Series B Funding

Prem AI

AI is the most powerful and pervasive technology of our time. Prem ensures that power is private, verifiable, and sovereign. We are a team of researchers, engineers, and entrepreneurs who believe this technology must be owned and stewarded by the organizations and people who adopt it. This is why we built Prem: an AI company headquartered in Switzerland, dedicated to developing private superintelligence in service of all.

SOPHiA GENETICS

SOPHiA GENETICS was founded in 2011 by biologists who had a vision to create a technology that could make a positive and lasting impact on the world, using data for good. We’ve built a revolutionary technology platform, SOPHiA DDM™, that rapidly distills complex data into actionable insights, enabling clinicians, researchers, and biopharma to reshape the way that we diagnose and treat cancer and rare inherited disorders. The AI fueling our platform learns from the complex genomic and multimodal data provided by our community of users to create a collective intelligence over time. By using the power of data and AI, we are expanding access to data-driven medicine and enabling the patients of today to help the patients of tomorrow. Our science is driven by unrelenting passion for our mission to transform patient care by expanding access to data-driven medicine globally. We wouldn’t be able to achieve all that we have – and all that we will – without our people, who are driven by our shared purpose to ensure that every patient worldwide has equitable access to precision medicine. Our virtues are our behaviors we exhibit every day, and our mantra “We Care” is our driving force.

PolaSight

PolaSight is a medical technology company developing advanced real-time imaging solutions designed to support surgical decision-making and improve precision during procedures. Our platform aims to help clinicians visualize tissue in real time, enhance workflow efficiency, and enable better patient outcomes. Founded in Switzerland, PolaSight is focused on translating cutting-edge imaging innovation into practical tools for the operating room and beyond.

Verretex

Verretex purchases low quality recycled glass fiber and uses our propriatary technology to regenerate their properties producing high quality glass fiber textiles for reuse in new products.

AlveoliX

Our Vision We aim at changing the way drug development research is done today by providing in-vitro models that reproduce the in-vivo environment in an unprecedented way. These in-vitro models, called organ-on-chips, will make it possible to better predict drugs’ responses in humans than standard in-vitro and in-vivo models and as a consequence to importantly reduce animal testing. Our Mission AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at improving preclinical decision-making and thus reducing drug development costs.